Taubert H, Meye A, Würl P
Institute of Pathology, Martin Luther University of Halle, Halle/Salle, Germany.
Cancer Res. 1996 Sep 15;56(18):4134-6.
We investigated the prognostic value of p53 mutation type for 145 soft tissue sarcoma patients. In a PCR-SSCP-sequencing analysis, 15 mutations were identified: 10 non-frameshift (non-fs) and 5 frameshift (fs) mutations. Patients possessing non-fs mutations had a significantly poorer prognosis than patients without p53 mutations (P = 0.014), according to Cox's multivariate analysis. In contrast, the survival of five patients with fs mutations was not affected by their mutation type. Furthermore, occurrence of lymph node metastases and recurrences was correlated with the mutation type; i.e., 4 of 10 and 5 of 10 patients with non-fs mutations showed lymph node metastases and recurrences, respectively, whereas none of the patients with fs mutations showed lymph node metastases and only one a recurrence. Therefore, for the evaluation of prognosis, we suggest applying not the p53 mutational status in general, but the specific type of mutation.
我们研究了p53突变类型对145例软组织肉瘤患者的预后价值。在聚合酶链反应-单链构象多态性-测序分析中,共鉴定出15个突变:10个非移码(non-fs)突变和5个移码(fs)突变。根据Cox多因素分析,具有非移码突变的患者预后明显差于无p53突变的患者(P = 0.014)。相比之下,5例具有移码突变患者的生存情况不受其突变类型的影响。此外,淋巴结转移和复发的发生与突变类型相关;即,10例具有非移码突变的患者中分别有4例和5例出现淋巴结转移和复发,而具有移码突变的患者均未出现淋巴结转移,仅有1例复发。因此,为评估预后,我们建议并非一般地应用p53突变状态,而是应用特定的突变类型。